Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (CSL)
1 other identifier
interventional
40
1 country
1
Brief Summary
This is a mono-centre, prospective, one-arm, unmask clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation compared to a single vision spectacle lens from the historical control group of another clinical trial NCT05331378. A total of 40 children will be recruited.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2023
CompletedFirst Posted
Study publicly available on registry
February 13, 2023
CompletedStudy Start
First participant enrolled
February 13, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 26, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 12, 2024
CompletedOctober 10, 2024
October 1, 2024
1.3 years
February 2, 2023
October 8, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Axial Length
Change in ocular axial length (mm) measured using Lenstar Optical Biometer.
12 months
Secondary Outcomes (1)
Spherical Equivalent Refraction
6 months and 12 months
Study Arms (1)
Test myopia control lenses (CSL)
EXPERIMENTALA pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
Interventions
A pair of myopia control spectacle lenses (test lenses) will be given to subjects to wear for 12 months
Eligibility Criteria
You may qualify if:
- Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the informed consent \& assent form.
- to 13 years old at time of informed consent and assent.
- Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.75 D in each eye.
- Astigmatism, if present, of not more than 1.50 D.
- Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
- Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
- Be in good general health based on his/her and parent's/guardian's knowledge. Absence of ocular disease with full ophthalmic examination. Without any ocular or systemic condition known to affect refractive status.
- Absence of strabismus by cover test at near or distance wearing correction.
- Absence of amblyopia
- Without ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.
You may not qualify if:
- Vulnerability of subject
- History of myopia control intervention
- Participation in any clinical study within 30 days of the Baseline visit.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Essilor R&D Centre Singapore
Singapore, 339346, Singapore
Related Publications (1)
Bao J, Yang A, Huang Y, Li X, Pan Y, Ding C, Lim EW, Zheng J, Spiegel DP, Drobe B, Lu F, Chen H. One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br J Ophthalmol. 2022 Aug;106(8):1171-1176. doi: 10.1136/bjophthalmol-2020-318367. Epub 2021 Apr 2.
PMID: 33811039BACKGROUND
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Andrew Tan
Essilor R&D Centre Singapore
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 2, 2023
First Posted
February 13, 2023
Study Start
February 13, 2023
Primary Completion
May 26, 2024
Study Completion
June 12, 2024
Last Updated
October 10, 2024
Record last verified: 2024-10